Trends in dupilumab persistence among patients with chronic rhinosinusitis with nasal polyps

Background: Establishing effective treatment algorithms for chronic rhinosinusitis with nasal polyps (CRSwNP) remains challenging, particularly concerning biologic therapies' discontinuation rates. Limited real-world data exist on the persistence of dupilumab, a biologic used in CRSwNP. We conducted a large-scale claims-based analysis to compare dupilumab discontinuation rates. Methodology: Utilizing the IBM MarketScan® Research Database, we identified CRS patients treated with dupilumab from July 2019 to December 2021. We assessed drug discontinuation rates, comorbidities, demographics, and surgical history using Kaplan-Meier curves and Cox proportional hazards models. Results: Of 1718 CRS patients on dupilumab, median age at initiation was 45 years, with 44% male. Dupilumab persistence varied by comorbidity, with patients with comorbid asthma exhibiting the longest median usage (652 days). Statistically significant differences in drug persistence were observed among comorbid conditions (p